Review and comment rules of national key monitoring drug prescriptions （medical orders）
- VernacularTitle:国家重点监控药品处方（医嘱）审核点评规则
- Author:
Liu YANG
1
,
2
;
Yong HAN
1
,
2
;
Qing SHEN
1
,
2
;
Yimeng ZHOU
1
,
2
;
Wei REN
1
,
2
;
Junfeng YAN
1
,
2
;
Rongsheng TONG
1
Author Information
1. Dept. of Pharmacy，Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital，Chengdu 610072，China
2. Sichuan Provincial Key Laboratory of Personalized Drug Therapy，the Affiliated Hospital of UESTC，Chengdu 610072，China
- Publication Type:Journal Article
- Keywords:
key monitoring drugs;
rational drug use;
review and comment rules;
medical institutions
- From:
China Pharmacy
2023;34(21):2561-2577
- CountryChina
- Language:Chinese
-
Abstract:
In order to standardize the review and comment of national key monitoring drug prescriptions （medical orders） by medical institutions at all levels， the Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital took the lead in compiling the Review and Comment Rules of National Key Monitoring Drugs prescriptions （Medical Orders） herein after referred to as the Rules in accordance with the Second Batch of National Key Monitoring Rational Drug Use List （hereinafter referred to as the List） issued by the National Health Commission confirmed in Jan. 13， 2023. According to the laws and drug instructions issued by the national drug regulatory department， clinical guidelines and expert consensus， combined with the actual situation of patients （including age， body weight， liver and kidney function）， the writing group classified the common and unreasonable drug use problems for 30 kinds of drugs included in the List and develop the review and comment details. After two rounds of Delphi method questionnaire research and experts’ online meetings， and reviewed by the steering committee， the final Rules was formed. The Rules aim to provide reference for the evaluation of the rational use of drugs included in the List by medical institutions， so as to realize the standardized management of key monitoring drugs， promote the rational drug use in medical institutions， and ensure the safety of drug use for patients.
